News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Rexahn Pharmaceuticals, Inc. Announce IND Submission for RX-3117


7/15/2013 10:38:04 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) announced today that Teva Pharmaceutical Industries has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for RX-3117, a novel oral small molecule chemotherapy agent, under a June 2009 Research and Exclusive License Option Agreement with Teva Pharmaceutical Industries Ltd. for RX-3117.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES